Acute Heart Failure – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of AHF for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s AHF forecast will answer the following questions:

• Of all people with AHF, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with AHF, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AHF over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts the following AHF patient populations:

• Diagnosed events
• Diagnosed events with hypertension
• Diagnosed events without hypertension
• Primary diagnosed events with hypotension
• Primary diagnosed events without hypotension
• Secondary diagnosed events with hypotension
• Secondary diagnosed events without hypotension
• Diagnosed events with reduced ejection fraction (HFrEF)
• Diagnosed events with preserved or mid-range ejection fraction (HFpEF / HFmrEF)

Note: Coverage may vary by country.